Expand GTBP Menu
GTBP MENU

GTBP Latest Press Releases

-- March 11, 2026 --

GT Biopharma to Participate in the 38th Annual Roth Conference Globe Newswire 7:00 AM

-- March 2, 2026 --

GT Biopharma Reports Full Year 2025 Financial Results Globe Newswire 7:00 AM

-- February 17, 2026 --

GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference Globe Newswire 7:30 AM

-- February 3, 2026 --

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3 Globe Newswire 8:30 AM

-- January 16, 2026 --

THE SCARCITY DOCTRINE: 5 Assets Securing the 2026 Material Cycle Globe Newswire 11:19 AM

-- January 15, 2026 --

GT Biopharma Announces IND Submission for GTB-5550 TriKE, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers Globe Newswire 8:30 AM

-- December 24, 2025 --

Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge Globe Newswire 6:00 AM

-- December 15, 2025 --

THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis Globe Newswire 10:54 AM

-- December 11, 2025 --

THE REALITY CHECK: 5 Assets Delivering Proof in a Speculative Market Globe Newswire 9:14 AM

-- November 19, 2025 --

GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials ACCESS Newswire 8:00 AM

-- November 14, 2025 --

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update Globe Newswire 9:00 AM

-- October 23, 2025 --

GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies Globe Newswire 9:00 AM
Market Data Delayed 15 Minutes